It has been demonstrated that tumor-associated B cells, plasma cells, or TLS are presented in the tumor microenvironment and are associated with improved survival and immunotherapy responsiveness in many types of cancers independent of TILs and PD-L1 expression in tumor tissues [254,255,256,257,258]. The gene discussed is CD274; the disease is neoplasm.